Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/10/2020
SIETES contiene 93129 citas

 
 
 1 a 20 de 282 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
WHO Solidarity trial consortium. Repurposed antiviral drugs for COVID-19 –interim WHO SOLIDARITY trial results. medRxiv 2020:15 de octubre. [Ref.ID 103745]
2. Cita con resumen
The RECOVERY Collaborative Group. Effect of hydroxychloroquine in hospitalized patients with covid-19. N Engl J Med 2020:8 de octubre. [Ref.ID 103732]
3.Enlace a cita original Cita con resumen
Skipper CP, Pastick KA, Engen NW, Bangdiwala AS, Abassi M, Lofgren SM, Williams DA, Okafor EC, Pullen MF, Nicol MR, Nascene AA, Hulisiek KH, Cheng MP, Luke D, Lother SA, MacKenzie LJ, Drobot G, Kelly LE, Schwartz IS, Zarychanski R, McDonald EG, Lee TC, Rajasingham R, Boulware DR. Hydroxychloroquine in nonhospitalized adults with early COVID-19. A randomized trial. Ann Intern Med 2020:16 de julio. [Ref.ID 103687]
4. Cita con resumen
Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, Brar I, Alangaden GJ, Ramesh MS, McKinnon JE, O'Neill W, Zervos M, Henry Ford COVID-19 Task Force. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. International Journal of Infectious Diseases 2020:1 de julio. [Ref.ID 103682]
5. Cita con resumen
Addis A, Ganazzani A, Trotta MP, Magrini N, for the Italian Medicines Agency Scientific Committee and COVID-19 Crisis Unit. Promoting better clinical trials and drug information as public health interventions for the COVID-19 emergency in Italy. Ann Intern Med 2020:16 de junio. [Ref.ID 103673]
9. Cita con resumen
10. Cita con resumen
Rome BN, Avorn J. Drug evaluation during the covid-19 pandemic. N Engl J Med 2020;382:11 de junio. [Ref.ID 103661]
11. Cita con resumen
Nguyen LS, Dolladille C, Drici M-D, Fenioux C, Alexandre J, Mira J-P, Moslehi JJ, Roden DM, Funck-Brentano C, Salem J-E. Cardiovascular toxicities associated with hydroxychloroquine and azithromycin: an analysis of the World Health Organization pharmacovigilance database. Circulation 2020:22 de mayo. [Ref.ID 103660]
12. Cita con resumen
Taylor P. COVID-19 round-up: medicines on trial. PMLiVE 2020:9 de junio. [Ref.ID 103659]
13. Cita con resumen
Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, Wu Y, Xiao W, Liu S, Chen E, Chen W, Wang X, Yang J, Lin J, Zhao Q, Yan Y, Xie Z, Li D, Yang Y, Liu L, Qu J, Ning G, Shi G, Xie Q. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ 2020;369:14 de mayo. [Ref.ID 103652]
14. Cita con resumen
Mahévas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel T-A, Lescure F-X, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky J-M, Michel M, Perrodeau E, et al.. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. BMJ 2020;369:14 de mayo. [Ref.ID 103651]
15. Cita con resumen
Boulware DR, Pullen MF, Bangdiwala AS, Pastik KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, et al.. A randomized trial of hydroxychloroquine as postexposure prophylaxis for covid-19. N Engl J Med 2020:1. [Ref.ID 103646]
17.Tiene citas relacionadas Cita con resumen
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet 2020:22 de mayo. [Ref.ID 103632]
20. Cita con resumen
Chorin E, Dai M, Shulman E, Wadhwani L, Bar-Cohen R, Barbhaiya C, Aizer A, Holmes D, Bernstein S, Spinelli M, Park DS, Chinitz LA, Jankelson L. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin. Nat Med 2020:24 de abril. [Ref.ID 103600]
Seleccionar todas
 
 1 a 20 de 282 siguiente >>